SPHK1 and acute myeloid leukemia: AML cells resistant to the combination of current chemotherapeutics (daunorubicin and cytarabine) are characterized by a unique upregulation of AC, GCS, and SPHK1 activity, as well as increased expression of ASAH1, UGCG, and SPHK1 [158].